When

Friday, September 24, 2021

11:00 AM-1:00 PM ET

WheRE

Webcast

faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Myron J. Levin, MD
Professor of Pediatrics and Medicine
University of Colorado School of Medicine
Denver, Colorado

Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine
Director, HIV Clinical Trials Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, Connecticut

Target Audience

This activity is intended for infectious disease, internal medicine, and other clinicians involved in the management of patients with mild or moderate coronavirus disease (COVID-19) who are at risk for clinical progression. 

Program Description

A panel of experts will discuss a series of educational topics related to the stratification of patients with COVID-19 based on risks of disease progression, current evidence and regulatory status for anti-SARS-CoV-2 monoclonal antibodies, and how to best utilize these treatment options to maximize patient outcomes and reduce health disparities.  

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the clinical profiles and trial data for current and emerging anti-SARS-CoV-2 monoclonal antibodies
  • Identify patients with mild-to-moderate COVID-19 who are at high risk for clinical progression
  • Treat patients who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current guidelines from the US Food and Drug Administration
  • Reduce barriers to the use of anti-SARS-CoV-2 monoclonal antibody therapies, including patient reluctance and healthcare disparities

Agenda Topics

  • What is the Current Status of Anti-SARS-CoV-2 Monoclonal Antibodies?
  • Who Should Be Treated With Anti-SARS-CoV-2 Monoclonal Antibodies?
  • How Do We Use Anti-SARS-CoV-2 Monoclonal Antibodies in Real-World Practice?
  • Where Are We Going With Anti-SARS-CoV-2 Monoclonal Antibodies?
  • How Can We Reduce Disparities in the Use of Anti-SARS-CoV-2 Monoclonal Antibodies?

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications.  Global Education Group is accredited by the American Association of Nurse Practitionres as an approved provider of nurse practitioner continuing education.  Provider number: 110121.  This activity is approved for 2.0 contact hour(s) (which includes xx hours of pharmacology).

Pharmacology hour(s) TBD after clinical content review.

Pharmacist Accreditation Statement

Global is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Credit Designation

Global designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-164-L01-P). This is an application-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must participate in the virtual event and complete the program post-test and evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Contact Information

For any other questions about this program, please contact Mara Simpson at msimpson@integritasgrp.com.

This activity is jointly provided by Global Education Group and Integritas Communications

This activity is supported by an educational grant from AstraZeneca.

Register Now

attend event
Related events
APR
08
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:00 PM-1:00 PM CT
Venue: Health Service Inc. - In-Person Event
Location: Montgomery, AL
Faculty: William S. Bradford, MD
APR
11
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:30 PM-1:30 PM CT
Venue: Cahaba Medical Care - In-Person Event
Location: Birmingham, AL
Faculty: Audrey R. Lloyd, MD
APR
17
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:00 PM-1:00 PM CT
Venue: Mobile County Health Dept. - In-Person Event
Location: Mobile, AL
Faculty: Audrey R. Lloyd, MD
APR
19
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:00 PM-1:00 PM CT
Venue: Mobile County Health Dept. - In-Person Event
Location: Mobile, AL
Faculty: William S. Bradford, MD
APR
22
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:00 PM-1:00 PM CT
Venue: Health Service Inc. - In-Person Event
Location: Montgomery, AL
Faculty: Audrey R. Lloyd, MD
APR
24
2024
Regional Meeting Series
1.00 CME/CE

BRIDGE HCV

Building Bridges To Reach People Who Inject Drugs With The Goal To Eliminate HCV

Time: 12:30 PM-1:30 PM CT
Venue: Cahaba Medical Care - In-Person Event
Location: Birmingham, AL
Faculty: Ellen F. Eaton, MD, MSPH, FIDSA